| Literature DB >> 33362789 |
Claire Tinel1,2,3, Agathe Vermorel1, Daniela Picciotto1, Lise Morin1, Arnaud Devresse1,4,5, Virginia Sauvaget2, Xavier Lebreton1, Laïla Aouni1, Dominique Prié3,6, Séverine Brabant6, Véronique Avettand-Fenoel3,7, Anne Scemla1, Marc Olivier Timsit3,8, Renaud Snanoudj9, Christophe Legendre1,2,3, Fabiola Terzi2, Marion Rabant2,3,10, Dany Anglicheau1,2,3.
Abstract
BK virus (BKV) replication increases urinary chemokine C-X-C motif ligand 10 (uCXCL10) levels in kidney transplant recipients (KTRs). Here, we investigated uCXCL10 levels across different stages of BKV replication as a prognostic and predictive marker for functional decline in KTRs after BKV-DNAemia. uCXCL10 was assessed in a cross-sectional study (474 paired urine/blood/biopsy samples and a longitudinal study (1,184 samples from 60 KTRs with BKV-DNAemia). uCXCL10 levels gradually increased with urine (P-value < 0.0001) and blood BKV viral load (P < 0.05) but were similar in the viruria and no BKV groups (P > 0.99). In viremic patients, uCXCL10 at biopsy was associated with graft functional decline [HR = 1.65, 95% CI (1.08-2.51), P = 0.02], irrespective of baseline eGFR, blood viral load, or BKVN diagnosis. uCXL10/cr (threshold: 12.86 ng/mmol) discriminated patients with a low risk of graft function decline from high-risk patients (P = 0.01). In the longitudinal study, the uCXCL10 and BKV-DNAemia trajectories were superimposable. Stratification using the same uCXCL10/cr threshold at first viremia predicted the subsequent inflammatory response, assessed by time-adjusted uCXCL10/cr AUC (P < 0.001), and graft functional decline (P = 0.03). In KTRs, uCXCL10 increases in BKV-DNAemia but not in isolated viruria. uCXCL10/cr is a prognostic biomarker of eGFR decrease, and a 12.86 ng/ml threshold predicts higher inflammatory burdens and poor renal outcomes.Entities:
Keywords: BK polyomavirus; CXCL10; kidney transplantation; prognostic biomarker; urinary chemokines
Mesh:
Substances:
Year: 2020 PMID: 33362789 PMCID: PMC7759001 DOI: 10.3389/fimmu.2020.604353
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561